Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 4Unknown 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5Expanded_access 1

Sponsor

Conditions

Nevus, Sebaceous of Jadassohn 4Oncogenic osteomalacia 3

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × burosumab × Clear all
NCT05357573 2024-07-09

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

Kyowa Kirin Co., Ltd.

Phase 4 Completed
9 enrolled

Oncogenic osteomalacia

NCT02304367 2024-05-06

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
17 enrolled 66 charts

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT04320316 2022-10-07

ENS

University of Alabama at Birmingham

Phase 4 Completed
1 enrolled 10 charts

Nevus, Sebaceous of Jadassohn

NCT02722798 2022-09-06

A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Kyowa Kirin Co., Ltd.

Phase 2 Completed
14 enrolled

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT03993821 2022-03-07

Burosumab for CSHS

Children's National Research Institute

Phase EARLY_PHASE1 Unknown
1 enrolled

Nevus, Sebaceous of Jadassohn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡